More NewsRead More
Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
August 11, 2014
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
August 08, 2014
Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
June 17, 2014
Mirati Therapeutics Reports First Quarter 2014 Financial Results and Provides Business Update
May 15, 2014
UPDATE: Wedbush Securities Initiates Coverage On Mirati Therapeutics, Inc. As Key Data Is Around The Corner
September 19, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here